Axio was founded in 2008 by Leo Mavely, a bio-engineer to develop novel bio-polymer platform based products for wound care. Axio has the distinction to be the first company from India to design, develop and commercialize an Emergency Haemostat for Trauma care.
The vision of Axio Biosolutions team is to develop affordable, high impact medical products that can solve unmet healthcare needs of emerging markets. Controlling life-threatening bleeding continues to be the major cause of death from traumatic injuries.
Axiostat® is its flagship product developed to reduce the mortality due to traumatic bleeding. Axio is a ISO 13485 certified company with an experienced team focused on bringing high-impact medical products to market.
Axiostat® uses a.c.t (axio clotting technology) to control severe haemorrhage within minutes. a.c.t is based on a bio-polymer platform that utilises cationic properties for medical applications. Axiostat® is a 100% chitosan dressing made from pure grade chitosan extracted from shellfish. Chitosan is a linear polysaccharide consisting of glucosamine and N-acetyl glucosamine chains and is derived mainly from shellfish. It has been used in many technical applications such as medical products, water purification, in cosmetics and as a fat-binding weight control product. Cationic nature of chitosan gives this polymer a muco-adhesive property which can be further activated for wound care applications. Chitosan salts are used as a matrix or scaffold material as well as in non-parenteral delivery systems for challenging drugs.
Chitosan has been in use for medical application like Chitosan gauze/bandage/sponge, since beginning of 21st century. However major challenges associated with chitosan based products are lack of consistency and presence of impurities. Axio uses a proprietary technology to filter, purify chitosan and result is end products without any variation in performance or safety features. Particularly Axio technology uses low poly-dispersity, high molecular weight raw material with a very pure, 100% chitosan, quick-acting Haemostat.
Axio products are constantly bench-marked with global harmonized standards and starting material, chitosan complies with the ASTM standard.and are made in ISO 13485 approved facilities. The main characteristics of Chitosan are: it is bio-compatible and bio-adhesive, it is 100% natural, contains 0% protein, has no exothermic reaction and it is easily broken due to glucosamine.
Axio envisages a future where contemporary knowledge of bio-materials, medicine and engineering will be integrated in designing novel solutions to address the huge unmet need in management of trauma and chronic-infectious wounds. They are a deep science medtech company with extensive R&D expertise in biomaterials. Our platform-based approach enables us to develop medical products that are engineered to enhance its efficacy even at higher scale. With such a vision, we introduced our first line of haemostatic products that are probably one of the best available trauma heamostats in the market today.
Axio’s research philosophy is to translate the bio-materials research into real-world products and bring them to patients’ bedside at an affordable cost. Here innovation is a daily practice as we explore uncharted territories in novel materials and technologies. The research & development team at Axio is developing novel solutions that are smarter, friendlier and quicker than the conventional products.
Axio benchmarks to global standards and follow appropriate regulatory guidelines in respective countries of operation. We follow a process that is based on a strong foundation of manufacturing quality standards, mutually beneficial relations with our customers, dealers and all professionals associated with us.